For a non-smoker, use standard clozapine initiation and titration, but recognize they generally need a lower maintenance dose than a smoker because tobacco smoke induces CYP1A2 and lowers clozapine concentrations.

Key practical point: dose to clinical response plus trough clozapine level, not smoking status alone. A commonly used trough therapeutic range is roughly 350-600 ng/mL (laboratory units may be reported as ng/mL or micrograms/L).

If a patient stops smoking while already stable on clozapine, their clozapine concentration can rise substantially within days. Specialist guidance commonly reduces the dose by about 30% to 50%, with close review and clozapine levels. Nicotine replacement and vaping generally do not produce the same CYP1A2 induction as combustible tobacco smoke.

Do not make rapid dose changes independently: monitor for sedation, confusion, seizures, orthostatic hypotension, tachycardia, constipation/ileus, and toxicity, while continuing mandated ANC monitoring. The current FDA Clozaril label specifically advises considering dose reduction when tobacco smoke exposure is discontinued.

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.